Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Nurix Therapeutics, Inc. (NRIX) vs SELLAS Life Sciences Group, Inc. (SLS)

Nurix Therapeutics, Inc. and SELLAS Life Sciences Group, Inc. are both Biotechnology companies. Nurix Therapeutics, Inc. and SELLAS Life Sciences Group, Inc. are of similar size ($2.5B and $2.4B). SELLAS Life Sciences Group, Inc. has the higher net margin (0.00% vs −928.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, SELLAS Life Sciences Group, Inc. leads on 9 and Nurix Therapeutics, Inc. on 5.

Valuation

Metric NRIX SLS Biotechnology median
P/E n/m n/m 7.88
P/S 69.73 209.18 11.47
P/B 6.37 15.96 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 57.67 196.06 10.73
Earnings yield (14.95%) (1.81%) (28.84%)
Free cash flow yield (11.88%) (1.75%) (23.03%)

Profitability

Metric NRIX SLS Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (982.37%) 0.00% 0.00%
Net margin (928.44%) 0.00% 0.00%
Free cash flow margin (828.28%) 0.00% 0.00%
Return on equity (80.30%) (39.63%) (57.72%)
Return on assets (60.57%) (36.54%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NRIX SLS Biotechnology median
Revenue growth (TTM) (58.40%) — 5.64%
EPS growth (last fiscal year) (5.90%) 50.00% —
Revenue growth, 5-year CAGR 36.35% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NRIX SLS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.34 18.83 4.73
Net debt to EBITDA 2.14 2.54 0.96

Dividend

Metric NRIX SLS Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric NRIX SLS Biotechnology median
Market cap 2.45b 2.37b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack